BioPharmSignal logoBioPharmSignal

Biotech News

Cellectar Biosciences Announces Subset of CLOVER WaM Clinical Trial Data Accepted for Presentation at the American Society of Clinical Oncology Conference 2026

Cellectar Biosciences (CLRB)Cellectar BiosciencesClinical readout

CLRB (CLRB) appears in the live feed after a catalyst-style update. The headline is surfaced in real time so readers can move from signal to source without leaving the product flow.

The source domain is clrb.com. BioPharmSignal keeps the ticker, timestamp, and source together for faster review before the wider market catches up.

The original release is available below in a new tab so readers can continue into the full source when needed.

Related news

CLRBCellectar Biosciences2026-07-15 11:30 EST

Cellectar Biosciences Announces Publication of Phase 1 Study of Iopofosine I 131 in Peer-Reviewed Journal Cancers

CLRBCellectar Biosciences2026-08-13 11:15 EST

Cellectar Biosciences Reports Second Quarter 2026 Financial Results and Provides Corporate Updates

COGTCogent Biosciences2026-06-12 12:00 EST

Cogent Biosciences Announces Detailed Data from APEX Pivotal Trial of Bezuclastinib in Patients with Advanced Systemic Mastocytosis at the 2026 European Hematology Association (EHA) Congress

FATEFate Therapeutics2026-08-14 11:00 EST

Fate Therapeutics Initiates Potentially Registrational RECLAIM-LN Clinical Trial of FT819 for the Treatment of Lupus Nephritis

RVMDRevolution Medicines2026-06-23 12:00 EST

Revolution Medicines Begins Treating Patients in RASolute 305, a Phase 3 Clinical Trial Evaluating Zoldonrasib in Combination with Chemotherapy as a First Line Treatment for Patients with RAS G12D Metastatic Pancreatic Cancer

IDYAIDEAYA Biosciences2026-06-15 10:00 EST

IDEAYA Biosciences Announces IDE892, a Potential Best-in-Class MTA-Cooperative PRMT5 Inhibitor, Initiates a Phase 1/2 Clinical Combination Study in MTAP-Deleted Pancreatic and Lung Cancers

MGNXMacroGenics2026-07-23 20:01 EST

MacroGenics Provides Clinical Update on Ongoing Phase 1 Study for MGC026

COGTCogent Biosciences2026-06-30 12:00 EST

Cogent Biosciences Announces Submission of New Drug Application (NDA) for Bezuclastinib in Advanced Systemic Mastocytosis (AdvSM)

NRIXNurix Therapeutics2026-08-04 11:00 EST

Nurix Announces $10 Million Milestone Payment Associated with Initiation of a Phase 1 Clinical Trial of a STAT6 Degrader

IDYAIDEAYA Biosciences2026-07-27 10:00 EST

IDEAYA Biosciences Announces IDE892, a Potential Best-in-Class MTA-Cooperative PRMT5 Inhibitor, Initiates Part 2 Monotherapy Expansion in the Phase 1/2 Study in MTAP-Deleted Pancreatic and Lung Cancers

View all latest news

Cellectar Biosciences

Phospholipid Drug Conjugate Platform Cellectar Biosciences develops cancer therapies using its Phospholipid Drug Conjugate platform, which is designed to deliver radioisotopes selectively to malignant cells while limiting off-target exposure. Iopofosine I 131 Iopofosine I 131 is the company’s lead radioconjugate and has produced clinical...

Recent company news

CLRBCellectar Biosciences2026-08-13 11:15 EST

Cellectar Biosciences Reports Second Quarter 2026 Financial Results and Provides Corporate Updates

CLRBCellectar Biosciences2026-07-30 12:05 EST

Cellectar Biosciences to Report Second Quarter Financial Results and Host a Conference Call on Thursday, August 13, 2026

CLRBCellectar Biosciences2026-07-15 11:30 EST

Cellectar Biosciences Announces Publication of Phase 1 Study of Iopofosine I 131 in Peer-Reviewed Journal Cancers

CLRBCellectar Biosciences2026-06-01 12:05 EST

Cellectar Biosciences to Highlight Compelling New Efficacy Data from Phase 2b CLOVER WaM Study of Iopofosine I 131 in r/r Waldenström Macroglobulinemia at the American Society of Clinical Oncology Annual Meeting

CLRBCellectar Biosciences2026-05-14 11:15 EST

Cellectar Biosciences Reports First Quarter 2026 Financial Results and Provides Corporate Updates

Stock data

Close
2.59 USD
Market cap
21.9M USD
Exchange
NASDAQ
Sector
Biopharma
Location
United States